November 22nd 2024
A phase 1 trial of α-lactalbumin vaccine for the treatment of patients with triple-negative breast cancer demonstrated safety and tolerability.
November 21st 2024
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations
View More
Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connection™: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
How We Do It™: Defining HER2 Low on Your Pathology Reports to Make Informed Decisions in Breast Cancer Treatment
View More
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
24th Annual International Congress on the Future of Breast Cancer® West
July 18-19, 2025
Register Now!
24th Annual International Congress on the Future of Breast Cancer® East
July 11-12, 2025
Register Now!
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
School of Breast Oncology® (SOBO) Slide & Lecture Library
Joyce O’Shaughnessy, MD
View More
Expert Discusses Abemaciclib Monotherapy in HR+/HER2- Breast Cancer
January 30th 2019In findings from the phase II next MONARCH 1 trial, single-agent abemaciclib continued to be safe and effective for patients with hormone receptor–positive, HER2-negative advanced breast cancer who have progressed on or following endocrine therapy.
Read More
Complete Response Letter From FDA Cites Issues With Sacituzumab Govitecan in TNBC
January 18th 2019In response to a biologics license application submitted for sacituzumab govitecan as a treatment for patients with metastatic triple-negative breast cancer who have received at least 2 prior therapies, the FDA has issued a complete response letter to Immunomedics, citing chemistry, manufacturing, and control matters.
Read More
Eribulin Emerges as a Candidate for Earlier Treatment of HER2- Metastatic Breast Cancer
January 17th 2019Eribulin mesylate (Halaven) demonstrated efficacy in the first-line for patients with aggressive HER2-negative metastatic breast cancer that have received prior treatment with a taxane in the (neo)adjuvant setting, according to results from the phase II MERIBEL trial.
Read More
Breast Cancer Surgery Choice May Have Long-Term Impact on QoL, Study Finds
January 3rd 2019Findings of a recent study suggest surgical choices in women with breast cancer may have long-term impacts on their quality of life. Investigators found that younger patients with breast cancer who underwent lumpectomy had better QOL outcomes than patients who had a mastectomy.
Read More
Patient-Reported Outcomes Differ Between Chemo and Endocrine Therapy in Breast Cancer
January 3rd 2019In an updated analysis of the phase III TAILORx trial in patients with breast cancer, investigators found that chemotherapy resulted in significantly more acute symptoms compared with endocrine therapy, however, the adverse events associated with endocrine therapy increased over time.
Read More